June 2020 – Proactive Investors: ReNeuron’s Michael Hunt explains new emphasis on its retinal and exosome technology programmes
June 2020 – Proactive Investors: One2One Virtual Event
11 June 2020: ReNeuron Group’s (LON:RENE) Michael Hunt pitches the company to investors at the Proactive One2One Virtual Event. The company’s a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.